淋巴管肌瘤病患者非脂肪性肾肿块的主动监测:利用CT特征和生长模式鉴别血管平滑肌脂肪瘤与肾癌
该研究对367例女性淋巴管肌瘤病患者每年行CT检查,对31例患者的37个非脂肪性肾肿块(活检、切除或随访≥5年)分析CT强化特征与生长模式,并与组织病理对照。结果显示持续增长或年增长>0.5 cm提示肾细胞癌,主动监测是合适的处理策略。
要点
- 非脂肪性肾肿块持续年增长>0.5 cm提示肾细胞癌,应活检。
- 多数非脂肪性肾肿块(29/33)呈年无变化、增大或缩小,仅少数持续增长。
- 活检或切除应保留给持续增长或年增长>0.5 cm的肿块。
核心结论
- 数据进一步证明,在长期随访的大型前瞻性研究中,主动监测是淋巴管肌瘤病患者非脂肪性肾肿块合适的处理策略。
研究设计与样本
- 前瞻性研究,367例女性(年龄21-75岁,平均47岁)每年行CT检查;对31例患者的37个非脂肪性肾肿块(活检、切除或随访≥5年)比较CT强化特征和生长模式与组织病理结果。
关键影像表现/征象
- 37个非脂肪性肾肿块中4个仅活检无随访CT:2个为不均匀肾细胞癌,1个为不均匀非脂肪性血管平滑肌脂肪瘤,1个为均匀非脂肪性血管平滑肌脂肪瘤。
- 33个有多次随访CT的肿块中,4个在某些年份持续年增长>0.5 cm,均为不均匀且活检证实为肾细胞癌。
- 其余29个肿块每年直径无变化、增大或缩小;8个不均匀,21个均匀;除1个外年增长均<0.5 cm,该例外为先缩小后增大。
诊断标准与关键数值
- 持续年增长>0.5 cm或随访中持续增长提示需活检或切除。
- 29个肿块中9个活检,均为非脂肪性肾肿块(5个均匀,4个不均匀)。
临床应用与阅片要点
- 对淋巴管肌瘤病患者的非脂肪性肾肿块可采取主动监测策略。
- 随访中关注生长速度和生长持续时间,持续增长或年增长>0.5 cm时考虑活检。
- 均匀或不均匀的非脂肪性肾肿块均可能为血管平滑肌脂肪瘤或肾细胞癌,需结合生长模式判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of this study was to report our experience with active surveillance of nonfatty renal masses in a large cohort of patients with lymphangioleiomyomatosis (LAM), correlate their CT features and patterns of growth with histopathology results, and provide guidelines for management.
SUBJECTS AND METHODS: Yearly CT examinations were performed of 367 women (age range, 21-75 years; mean age, 47 years). For the 31 patients with 37 nonfatty renal masses that were biopsied, excised, or followed for ≥ 5 years, CT enhancement characteristics and patterns of growth were compared with the histopathology results.
RESULTS: Four of 37 nonfatty renal masses were biopsied without follow-up CT examinations: Two were heterogeneous renal cell carcinomas (RCCs), one was a heterogeneous nonfatty angiomyolipoma (AML), and one was homogeneous nonfatty AML. In the remaining 33 nonfatty renal masses with multiple follow-up CT examinations, two growth patterns were identified. Four showed a continuous increase in size of > 0.5 cm/y in some years, and all four in this first group were heterogeneous and were biopsy-proven RCC. The second group was composed of the remaining 29 masses. These 29 masses showed yearly no change, increase, or decrease in diameter. Eight were heterogeneous, and 21 were homogeneous. Of the masses showing a yearly increase, the increase was < 0.5 cm/y in all except one. In the one exception, the increase followed a decrease. Nine of the 29 masses were biopsied, and all nine were nonfatty renal masses (five homogeneous, four heterogeneous).
CONCLUSION: Our data provide further evidence in a large prospective study with longterm follow-up that active surveillance is an appropriate strategy in the management of nonfatty renal masses in patients with LAM. Our analysis of the growth patterns reveals duration of growth in addition to growth rate as criteria for biopsy or excision. Biopsy should be reserved for nonfatty renal masses that show sustained growth or growth > 0.5 cm/y during follow-up.
引用
- Avila NA, Dwyer AJ, Moss J, et al. Active Surveillance of Nonfatty Renal Masses in Patients With Lymphangioleiomyomatosis: Use of CT Features and Patterns of Growth to Differentiate Angiomyolipoma From Renal Cancer. AJR Am J Roentgenol. 2017. PMID: 28678574. doi:10.2214/AJR.16.17530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。